Cutaneous reaction to oral celecoxib with positive patch test

Alonso, Juanjo; Ortega, J. Domínguez; Gonzalo, M. J. Fuentes

doi:10.1111/j.0105-1873.2004.00271i.x

Cited by 6 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our cases, drug imputability was promptly confirmed by patch testing on residual lesions, as described for several NSAIDs (1, 2, 11, 12), including celecoxib (13–15). Despite the pharmacological similarity between etoricoxib and celecoxib, no cross‐reaction was observed between these molecules, as only the latter is a sulfonamide‐related drug.…”

Section: Discussionsupporting

confidence: 70%

Fixed drug eruption caused by etoricoxib - 2 cases confirmed by patch testing

Andrade

Gonçalo

2011

Contact Dermatitis

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 70%

Fixed drug eruption caused by etoricoxib - 2 cases confirmed by patch testing

Andrade

Gonçalo

2011

Contact Dermatitis

View full text Add to dashboard Cite

“…To date, a patch test, LTT or oral challenge test have been performed in only 10 reported cases of celecoxib‐induced drug eruption in the English‐language published work (Table 1). 2–9 A positive patch test for celecoxib was reported in six of eight evaluable cases, an LTT was positive in two of three cases, and an oral challenge test was positive in two of two cases. Thus, celecoxib was identified as the causative drug by one or more allergy test in nine of 10 cases.…”

Section: Cases Of Celecoxib‐induced Drug Eruption Detected With a Pamentioning

confidence: 97%

“…Celecoxib was first used in the USA in 1999 1 and is now in common use worldwide due to its lower rate of gastrointestinal irritation compared to non‐selective NSAIDs 2 . With increased use, there has been an increase in the reports of drug eruptions due to celecoxib, 1 but only a few cases with diagnosis using tests such as the patch test, lymphocyte transformation test (LTT) or oral challenge test have been described 2–9 . Here, we report a case of erythema multiforme‐type drug eruption due to celecoxib that showed a positive patch test.…”

Section: Cases Of Celecoxib‐induced Drug Eruption Detected With a Pamentioning

confidence: 97%

Celecoxib-induced erythema multiforme-type drug eruption with a positive patch test

Arakawa¹,

Nakai²,

Katoh³

2011

The Journal of Dermatology

View full text Add to dashboard Cite

Celecoxib Erythema multiforme-type drug eruption in an elderly patient: case reportA 79-year-old woman developed an erythema multiforme-type drug eruption while receiving celecoxib for stage IV squamous cell lung cancer.The woman presented with a 1-day history of faint erythema on her face. She had been treated with oral celecoxib (400 mg/day for 7 days) [time to reaction onset not clearly stated] and erlotinib for pain and control of lung cancer, which had been diagnosed 10 months earlier. Laboratory analysis revealed a slightly elevated WBC count and CRP level. A drug eruption due to celecoxib or erlotinib was considered, but treatment was maintained. Topical betamethasone was initiated but, 3 days later, the erythemas had developed over her whole body; a skin biopsy was taken.Celecoxib and erlotinib were withdrawn. Within 10 days of treatment with olopatadine, difluprednate and hydrocortisone butyrate, the erythema had resolved. Histopathological analysis revealed a mild inflammatory infiltrate with subepidermal oedema in the upper dermis, and partial liquefaction degeneration at the dermalepidermal interface with a lymphocytic infiltrate. Patch testing was positive for celecoxib, and an erythema multiforme-type drug eruption due to celecoxib was diagnosed. Erlotinib was reintroduced, with no further symptoms indicating a drug eruption.Arakawa Y, et al. Celecoxib-induced erythema multiforme-type drug eruption with a positive patch test.

show abstract

“…Celecoxib is a benzene sulfonamide derivative containing a sulfonamide. This perhaps explains the numerous cutaneous side effects recorded with various celecoxib treatments, including maculopapular eruption, cutaneous vasculitis, allergic vasculitis, toxic epidermal necrolysis, urticaria and angioedema, Sweet’s syndrome, anaphylaxis, photosensitivity, and erythema multiforme 2 . However, there is no previous reported case of SDRIFE (symmetrical drug‐related intertriginous and flexural exanthema) caused by celecoxib.…”

mentioning

confidence: 99%